Advertisement
Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment
(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday that it has completed bioanalytical method development under its prior agreement with Altasciences.
The company now plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
The blood and plasma samples collected are part of a dose response study in a humanized mouse model.
The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
read more
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews
|
795天前
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.
RTTNews
|
1051天前
Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
RTTNews
|
1151天前
Swiss Market Ends On Weak Note
Save for a brief while around mid morning when it edged slightly above the flat line, Switzerland's benchmark index SMI remained in negative territory on Friday amid concerns about high tech valuation and fading hopes of an interest rate cut by the Federal Reserve next month.
RTTNews
|
4小时35分钟前
European Markets Close Weak On Growth Concerns, Fading Fed Rate Cut Hopes
European stocks closed weak on Friday amid concerns about high tech valuations, and fading hopes of a Federal Reserve rate cut next month following hawkish comments from a few central bank officials.
RTTNews
|
4小时57分钟前
Canadian Market Rebounds From Early Setback; Technology, Energy Stocks Rise
After opening with a big negative gap and dropping further down into the red Friday morning, the Canadian benchmark S&P/TSX Composite Index recovered gradually and was up modestly above the flat line a little past noon.
RTTNews
|
6小时7分钟前
Bay Street Likely To Open On Weak Note
Lower Canadian and U.S. futures and weak metal prices point to a negative open for stocks on Bay Street Friday morning. Energy stocks may find some support thanks to higher crude oil prices and help limit the downside.
RTTNews
|
10小时50分钟前
FTSE 100 Down Sharply As Bond Yields Climb Higher
UK stocks are falling on Friday with bond yields rising amid speculation Chancellor Rachel Reeves may backtrack on budget plans. The possibility of the Bank of England refraining from cutting interest rates due to fiscal concerns has raised concerns about fiscal and economic outlook.
RTTNews
|
11小时48分钟前
